Cinnamaldehyde, by altering metabolic processes like the activation of AMPK and the inhibition of sterol regulatory element-binding protein 1c (SREBP-1c), offers hope in improving lipid utilization and reducing hepatic steatosis. Here, SREBF1 is linked to fatty liver disease.